Posaconazole efficacy in a murine disseminated infection caused by Paecilomyces lilacinus

J Antimicrob Chemother. 2009 Feb;63(2):361-4. doi: 10.1093/jac/dkn497. Epub 2008 Dec 2.

Abstract

Objectives: We have compared the efficacy of posaconazole and amphotericin B in an experimental murine model of paecilomycosis.

Methods: Immunosuppressed mice were treated with posaconazole at 25, 50, 75 or 100 mg/kg/day orally, amphotericin B at 1.5 or 3 mg/kg/day intraperitoneally or liposomal amphotericin B at 5 mg/kg/day intravenously. Treatment began 1 day after infection and continued for 10 days post-infection. Two strains of Paecilomyces lilacinus were tested.

Results: Posaconazole at 50 mg/kg/day was the only treatment able to significantly reduce fungal loads in the spleens, kidneys and livers of the mice infected by each of the two strains.

Conclusions: The results suggest that posaconazole may have a clinical role in the treatment of disseminated paecilomycosis.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / administration & dosage
  • Amphotericin B / therapeutic use
  • Animals
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / therapeutic use*
  • Colony Count, Microbial
  • Kidney / microbiology
  • Liver / microbiology
  • Male
  • Mice
  • Mycoses / drug therapy*
  • Mycoses / microbiology
  • Paecilomyces / drug effects*
  • Spleen / microbiology
  • Triazoles / administration & dosage
  • Triazoles / therapeutic use*

Substances

  • Antifungal Agents
  • Triazoles
  • liposomal amphotericin B
  • posaconazole
  • Amphotericin B